Zolpidem
Viewing r1 — Apr 28, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Zolpidem is a synthetic sedative-hypnotic of the imidazopyridine class. It is the most widely prescribed of the "Z-drugs," structurally unrelated to benzodiazepines despite sharing their receptor target. Zolpidem is a positive allosteric modulator of GABA-A receptors, producing its effects by enhancing inhibitory signaling with strong preference for the sleep-mediating α1 subunit.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
benzodiazepines, zopiclone, zaleplon +1 morebenzodiazepines, zopiclone, zaleplon, alcohol show less
Synthesized at Synthelabo in Paris during the early 1980s, zolpidem was first approved in Europe in 1988 and received FDA approval in 1992 as Ambien.[2] It became the most prescribed hypnotic in the United States, and the FDA's 2013 sex-specific dose reduction made it a landmark case for pharmacokinetic differences between men and women.[3] It remains the benchmark comparator in clinical trials of novel sleep agents.
Subjective effects include rapid sedation, sleep-onset facilitation, anterograde amnesia, and at higher doses, euphoria and visual hallucinations. At therapeutic doses the experience is unremarkable drowsiness progressing to sleep; at supratherapeutic doses a hallucinatory twilight emerges, defined by a distinctive inability to recognize one's own impairment.[4] Complex sleep behaviors — sleepwalking, sleep-driving, sleep-eating — occur even at prescribed doses in susceptible individuals, typically with complete amnesia.[5]
Physical dependence develops at high doses, with withdrawal seizures documented at 200–500 mg/day,[6] though single-agent acute toxicity is low and reversible with flumazenil.[7] The defining chronic risk is persistent cognitive and psychomotor impairment during nighttime awakening — impairment to which tolerance does not develop even after weeks of nightly use[8][9] — compounded by unpredictable complex sleep behaviors that endanger users and bystanders. Three decades of clinical use and extensive post-marketing surveillance provide a robust evidence base, though individual susceptibility to complex sleep behaviors remains uncharacterized.
History[edit]
Discovery
Zolpidem was synthesized at Synthelabo, a French pharmaceutical company later acquired by Sanofi, as part of a program targeting imidazopyridine compounds with selective hypnotic properties. The design exploited the imidazo[1,2-a]pyridine scaffold to achieve selectivity at α1-containing GABA-A receptors — a deliberate departure from the non-selective benzodiazepines that had dominated sedative prescribing for two decades. The resulting compound retained full hypnotic efficacy while showing reduced anxiolytic and muscle-relaxant activity, a pharmacological profile that would define the emerging "Z-drug" class.
Clinical adoption
First approved in Europe in 1988 under the brand name Stilnox, zolpidem received FDA approval in 1992 as Ambien and became the most widely prescribed hypnotic in the United States by the early 2000s.[2] Extended-release, sublingual, and oral spray formulations followed between 2005 and 2007. In 2013, the FDA mandated a dose reduction for women — from 10 mg to 5 mg immediate-release — after pharmacokinetic data showed that 15% of women retained blood levels above the impairment threshold at 8 hours post-dose.[3]
Post-marketing surveillance
Between 2003 and 2012, the FDA Adverse Event Reporting System accumulated extensive reports of complex sleep behaviors — sleep-driving, sleepwalking, sleep-eating — associated with zolpidem.[5] Media coverage during 2006–2009 complicated interpretation of true incidence versus reporting artifacts, but the volume of reports prompted a boxed warning update and elevated clinical awareness of zolpidem's capacity to produce complex automatisms during apparent sleep.
The name "zolpidem" follows pharmaceutical compounding conventions with no particular etymological significance. Under the brand name Ambien, the compound acquired a distinctive cultural identity in the 2000s — "Ambien stories" became a recognized genre of anecdote in which users described elaborate activities (cooking, online shopping, sending messages) performed during apparent sleep with no subsequent memory.
Chemistry[edit]
Structural class
Zolpidem belongs to the imidazo[1,2-a]pyridine structural class — a bicyclic system of fused imidazole and pyridine rings. This places it in the Z-drug group alongside zopiclone (a cyclopyrrolone) and zaleplon (a pyrazolopyrimidine): three structurally distinct non-benzodiazepine compounds that share a mechanism of action at the GABA-A benzodiazepine binding site but bear no structural resemblance to the 1,4-benzodiazepine scaffold. The imidazopyridine core drives zolpidem's selectivity for the α1 subunit, arising from specific interactions at the α/γ subunit interface.[1]
Molecular properties
| Molecular formula | C₁₉H₂₁N₃O |
| Molecular weight | 307.4 g/mol |
The molecule features a 4-methylphenyl group at the 2-position of the imidazopyridine ring, a methyl group at the 6-position of the pyridine ring, and an N,N-dimethylacetamide side chain at the 3-position. The acetamide moiety contributes to pharmacological activity and moderate aqueous solubility. Zolpidem is weakly basic and lipophilic, facilitating rapid absorption and blood-brain barrier penetration consistent with its short onset time.[10]
Stereochemistry
Zolpidem is achiral — the molecule contains no stereocenters and is dispensed as a single molecular entity, not a racemic mixture. This distinguishes it from some related hypnotics where enantiomers have differential activity (e.g., eszopiclone, the S-enantiomer of zopiclone).
Pharmacology[edit]
Mechanism of action
Zolpidem is a positive allosteric modulator of GABA-A receptors, binding at the benzodiazepine site located at the α/γ subunit interface. It does not directly open the chloride channel — it enhances the effect of GABA when GABA is already present, increasing inhibitory signaling in the brain.
Unlike classical benzodiazepines, zolpidem binds preferentially to GABA-A receptors containing the α1 subunit.[11][12][1] Structural studies confirmed that this selectivity traces to a single amino acid difference at the binding site.[13][1] The practical consequence: sedative and sleep-promoting effects (α1-mediated) predominate at therapeutic doses, while the anxiolytic, muscle-relaxant, and anticonvulsant properties of non-selective benzodiazepines remain largely absent.[12]
Zolpidem also "primes" α1-containing receptors for longer activity durations — a mechanistic feature distinct from classical benzodiazepines.[14] Flumazenil, a benzodiazepine-site antagonist, fully reverses zolpidem's effects, confirming shared binding-site occupancy.[7][10]
Paradoxical consciousness-promoting effects
In patients with severe brain injury and disorders of consciousness, zolpidem has paradoxically been reported to improve arousal.[15] The hypothesized mechanism involves reversal of pathological over-inhibition in damaged brain circuits. This application is supported only by case series; the effect occurs in a minority of patients and lasts only as long as the drug is active.
Pharmacokinetics
Zolpidem is rapidly absorbed after oral administration, with bioavailability of approximately 70% and peak plasma levels reached within about 1.6 hours.[10][16] The half-life is short — 1.5 to 3.2 hours in the general population[10] — placing it at the fast-acting end of the sedative-hypnotic spectrum.
Women achieve approximately 50% higher peak levels and roughly double the overall drug exposure compared to men at the same dose.[16][17] This difference drove the FDA's 2013 label change: 15% of women versus 3% of men retained blood levels above the impairment threshold at 8 hours after a 10 mg dose.[3]
Food reduces absorption by roughly 15–25%; taking zolpidem on an empty stomach is recommended for fastest onset.[18]
Metabolism
Zolpidem is metabolized in the liver primarily by CYP3A4, with smaller contributions from CYP2C9 and CYP1A2.[19][18] All metabolites are inactive.[10]
The drug does not induce its own metabolism or activate major drug-metabolizing enzyme pathways at therapeutic doses.[20] Excretion occurs primarily through the kidneys as inactive breakdown products.[10]
Neuroscience[edit]
Where it acts
Zolpidem's α1-selective GABA-A modulation concentrates its effects in brain regions where that subunit is densely expressed. The thalamic reticular nucleus — a structure that generates sleep spindles — responds to zolpidem with increased spindle density and sigma-frequency power.[21][22] The hippocampus, also rich in α1-containing receptors, underlies the prominent anterograde amnesia: new memory formation is suppressed while previously consolidated memories remain accessible.[9]
At supratherapeutic doses, the hallucinatory state likely reflects disrupted sensory gating in thalamocortical circuits — internally generated perceptual content emerges before complete sedation, producing a hypnagogic twilight.[4] Complex sleep behaviors (sleepwalking, sleep-driving) involve a dissociation in which motor circuits remain active while cortical awareness networks are deeply inhibited.[5]
Why it matters
Zolpidem's reinforcement at high doses are explained by disinhibition of dopamine neurons in the ventral tegmental area — the same reward circuitry engaged by benzodiazepines and alcohol.[4][23][6] This mechanism underlies the dose escalation and compulsive use patterns documented in recreational contexts.
The paradoxical consciousness-promoting effect in brain-injured patients[15] involves a fundamentally different mechanism, possibly reversing pathological over-inhibition in damaged circuits rather than adding sedation.
No genetic or physiological biomarker predicts which individuals will develop complex sleep behaviors — susceptibility factors are entirely uncharacterized. The mechanism by which tolerance develops to sedative effects at high doses but not to cognitive impairment during nighttime awakening[9] is unexplained, and may involve distinct populations of α1-containing receptors in sleep-promoting versus cognitive circuits.
Subjective Effects[edit]
At prescribed doses, zolpidem's experiential profile is sparse — sedation descending into sleep, with little subjective content to recall. This changes markedly at supratherapeutic doses, where a qualitatively different state emerges: a hypnagogic twilight characterized by hallucinations, euphoria, cognitive disconnection, and the distinctive inability to recognize impairment.[4] Set and setting shape the character of the hypnagogic content but do not reliably prevent dangerous automatisms — complex sleep behaviors can occur regardless of environment.[5]
Compared to benzodiazepines at equivalent sedative doses, zolpidem intoxication is more perceptually distorted and less anxiolytic — the α1 selectivity pushes the experience toward a dreamlike, hallucinatory space rather than the calm disinhibition typical of non-selective GABAergic agents. Among the Z-drugs, zolpidem's longer duration and higher abuse-potential signal relative to zaleplon make it the more commonly misused compound.
Effect Grid
At common recreational doses (10–20 mg oral), effects extend beyond sedation into a distinctive altered state. Euphoria emerges alongside pronounced sedation. Cognitive disconnection intensifies — thought processes become disorganized and dreamlike. Anterograde amnesia is prominent; events during this period may not be recalled. Delusions of sobriety are characteristic: users frequently believe they are functioning normally despite obvious impairment.
Physically, motor coordination is significantly degraded. Slurred speech, unsteady gait, and difficulty with fine motor tasks are typical. Muscle relaxation is pronounced.
Complex sleep behaviors (sleepwalking, sleep-eating) become more likely at this range. Functional impairment is substantial — the individual should not attempt any task requiring coordination or judgment. Duration of noticeable effects extends to 4–6 hours.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual haze / noise · Spatial disorientation · Dreaming enhancement · Depth perception distortion · Peripheral misidentification · Geometry · Music enhancement · Auditory enhancement · After-images · Visual drifting · Visual magnification · Visual processing suppression · External hallucinations · Object activation · Object transformations · Internal hallucinations · Shadow people · Auditory hallucinations · Gustatory hallucination
Peripheral misidentification · Geometry · Music enhancement · Auditory enhancement · After-images · Visual drifting · Visual magnification · Visual processing suppression · External hallucinations · Object activation · Object transformations · Internal hallucinations · Shadow people · Auditory hallucinations · Gustatory hallucination
Bodily heaviness · Muscle relaxation · Nausea · Headache · Nystagmus (eye wobbles) · Dry mouth · Laughter fits · Sexual arousal enhancement · Tactile euphoria · Body schema distortion · Appetite enhancement · Abnormal heartbeat · Vomiting · Tactile hallucination
Headache · Nystagmus (eye wobbles) · Dry mouth · Laughter fits · Sexual arousal enhancement · Tactile euphoria · Body schema distortion · Appetite enhancement · Vomiting · Tactile hallucination
Information processing suppression · Memory suppression · Thought deceleration · Confusion · Language suppression · Memory fragmentation · Pattern recognition suppression · Thought disorganization · Cognitive euphoria · Compulsive redosing urge · Suggestibility enhancement · Amnesia · Delusions
Confusion · Language suppression · Memory fragmentation · Pattern recognition suppression · Thought disorganization · Cognitive euphoria · Suggestibility enhancement · Amnesia · Delusions
Euphoria · Empathy enhancement · Dysphoria · Anxiety · Irritability
Irritability
Automaticity · Cognitive disconnection
Timeline
First perceptible effects: subtle drowsiness, mild heaviness in the limbs, and a gentle cognitive slowing. At therapeutic doses, this may feel indistinguishable from natural tiredness.
Sedation deepens noticeably. Eyelid heaviness, motor slowing, and the first hints of anterograde amnesia emerge. At supratherapeutic doses, mild euphoria and cognitive loosening become apparent.
Maximum sedation and hypnotic effect, centered around Tmax (~1. 6 hours). At therapeutic doses, sleep onset occurs during this phase.
Effects gradually diminish from peak intensity. Sedation remains but loosens. Cognitive function begins partial recovery, though amnesia may still be operating.
Sedation fades to residual drowsiness. Motor coordination and cognitive clarity improve but remain below baseline. The short half-life (1.
Residual next-morning effects: mild cognitive dulling, subtle psychomotor impairment, and possible drowsiness. Women are at higher risk of persistent impairment due to higher plasma levels at 8 hours post-dose.
⚠ Do not drive or operate machinery until fully alert — next-morning impairment is documented even at recommended doses, particularly in women and the elderly.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Severe
- Tolerance buildup
- slow
- Tolerance reset
- —
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- benzodiazepines · zopiclone · zaleplon
Toxicity
Acute toxicity
Single-agent zolpidem poisoning is relatively benign and rarely requires intervention beyond supportive care.[18] Zolpidem produces less acute toxicity than short-acting benzodiazepines such as triazolam or midazolam.[10] Overdose typically presents as short-lasting coma with pinpoint pupils, reversible by flumazenil.[7]
Combination with CNS depressants substantially increases lethality. Single-agent fatalities are rare; lethal poisonings typically involve co-ingestion of alcohol, opioids, or other sedatives. Respiratory depression in combination overdose requires immediate airway management.
Chronic toxicity
Long-term use carries several risks that do not resolve with continued dosing:
- Persistent cognitive impairment: Memory, attention, and coordination deficits during nighttime awakening do not diminish over weeks of nightly use — tolerance to these impairments does not develop.[9]
- Falls and fractures: Risk is disproportionately elevated in elderly patients. Meta-analytic evidence shows that sedative hypnotic benefits in older adults are small while fall and cognitive impairment risks are clinically significant.[24][25] Zolpidem initiation also increases fall-related fracture risk in dialysis patients.[26]
- Cognitive decline: The association between Z-drug use and dementia risk remains under investigation. Current evidence suggests Z-drugs are not independently associated with global cognitive impairment in middle-aged and older insomnia patients, unlike benzodiazepines.[27][25]
Psychological risks
Complex sleep behaviors
Zolpidem is associated with complex behaviors during apparent sleep: sleepwalking, sleep-eating, sleep-driving, sleep-conversation, and taking additional medication while asleep.[5][28] These occur at therapeutic doses in susceptible individuals, with complete amnesia for events. No biomarker predicts who is at risk.
Hallucinations and delusions of sobriety
At supratherapeutic doses (≥15 mg), visual and auditory hallucinations, cognitive disconnection, and delusion-like phenomena emerge dose-dependently.[4] At extreme recreational doses (50–200+ mg), frank psychotic features and thought disorganization have been reported.[6]
A distinctive risk is impaired self-assessment of intoxication — users cannot recognize their impaired state, increasing the danger of driving, operating machinery, or taking additional doses while subjectively feeling competent.
Amnesia
Anterograde amnesia begins at therapeutic doses and intensifies with dose escalation. Co-administration with imipramine has been documented to worsen amnesia.[10]
Tolerance & dependence
At therapeutic doses (5–10 mg), tolerance to the sleep-promoting effect does not develop over 27 consecutive nights,[8] distinguishing zolpidem from triazolam. Tolerance to sedative effects does develop with chronic high-dose use, however, driving dose escalation for euphoric effects.[6]
The paradox: patients maintain sleep benefit but never adapt to the cognitive impairments produced during nighttime awakening.[9] At the cellular level, dependence involves functional uncoupling between GABA and benzodiazepine binding sites rather than receptor loss.[29] Animal studies show that repeated zolpidem produces tolerance and withdrawal comparable to diazepam.[30]
Physical dependence is documented at supratherapeutic doses. Withdrawal symptoms include anxiety, rebound effect insomnia, restlessness, tingling sensations, and flu-like symptoms, progressing to seizures in severe cases.[6][31] Cases of extreme dependence at 200–500 mg/day with seizures on abrupt discontinuation have been reported.[6] Among elderly patients prescribed benzodiazepines or Z-drugs for three or more months, 45.3% met dependence criteria.[32]
Drug interactions
Zolpidem's interaction profile involves two mechanisms: altered metabolism (primarily through CYP3A4) and additive CNS depression.
CYP3A4 inhibitors — ketoconazole, itraconazole, clarithromycin, erythromycin, ritonavir, and others — increase zolpidem levels and prolong its effects.[19] CYP3A4 inducers — rifampin, carbamazepine, St. John's Wort, phenytoin — decrease levels and may reduce efficacy.[33]
Co-administration with other CNS depressants produces additive sedation and respiratory depression:
- Alcohol: Enhanced sedation and potentially lethal respiratory depression[34]
- Opioids: Additive respiratory depression with risk of fatal outcome
- Benzodiazepines: Additive GABA-A modulation and enhanced sedation
- Imipramine: Worsened anterograde amnesia[10]
- Chlorpromazine: Decreased alertness[10]
Flumazenil fully reverses zolpidem's effects and serves as the specific antidote in overdose.[7][10]
Contraindications
- Known hypersensitivity to zolpidem or formulation components (absolute)
- Prior complex sleep behaviors on zolpidem (absolute) — recurrence risk is high and unpredictable
- Severe liver impairment (absolute) — reduced clearance produces dangerously elevated blood levels[10]
- Severe respiratory insufficiency (relative) — zolpidem modestly reduces breathing drive; risk increases with concurrent CNS depressants
- Obstructive sleep apnea (relative) — respiratory depression warrants cautioncitation needed
- Myasthenia gravis (relative) — GABAergic enhancement may worsen muscle weakness
- Active substance use disorders (relative) — documented abuse potential at supratherapeutic doses[4]
- Pregnancy (relative) — crosses placenta; risk of breathing depression in newborns[18]
- Children (not approved) — hallucinations reported; not recommended[18]
- Elderly (use with caution) — elevated fall/fracture risk; reduced clearance; dose reduction to 5 mg recommended[35][24]
Harm Reduction[edit]
Forms & Identification
Zolpidem circulates primarily as pharmaceutical tablets in immediate-release, extended-release, sublingual, and oral spray formulations. Counterfeit tablets bearing the Ambien imprint have been identified in unregulated markets, sometimes containing incorrect doses or substituted active ingredients. Because legitimate pharmaceutical zolpidem is widely available by prescription and generic cost is low, most diverted supply consists of genuine product — but verification of source remains important for anyone obtaining the drug outside a pharmacy.
Guidelines
- Take zolpidem immediately before getting into bed — not while finishing tasks, watching television, or expecting to stay awake
- Use the lowest effective dose; women are recommended 5 mg immediate-release due to slower clearance
- Do not take a second dose during the night
- Take on an empty stomach for fastest onset; food delays absorption by 15–25%
- Remove car keys, lock doors, and secure kitchen appliances before dosing if complex sleep behaviors are a concern
- Avoid nightly use beyond 2–4 weeks without medical reassessment — dependence risk increases with duration and dose
- If dose escalation has occurred (taking more than prescribed for effect), taper gradually; do not stop abruptly at doses above 10 mg/day
Set & Setting
Zolpidem should be taken only when a full night's sleep (7–8 hours) is available, in a safe environment with no access to car keys, stoves, or other hazards. The risk of complex sleep behaviors means the sleeping environment itself is a harm reduction variable — removing access to dangerous objects or exits reduces the consequences of sleepwalking or other automatisms. A trusted person nearby who is aware the drug has been taken can intervene if complex behaviors emerge.
Aftercare & integration. For those using zolpidem therapeutically, the primary aftercare concern is next-morning impairment. Cognitive and psychomotor deficits persist into morning hours, particularly in women and at doses above 5 mg. Do not drive or operate machinery until fully alert. If residual grogginess is persistent, discuss dose reduction with a prescriber.
For recreational use, the amnesia and automatism risk mean that checking for evidence of nighttime activity (sent messages, displaced objects, food preparation) the next morning is prudent. If complex sleep behaviors have occurred, the drug should not be used again without medical consultation.
Recovery & Support
Zolpidem dependence most commonly develops through gradual dose escalation from a legitimate prescription. Recognizing the pattern — needing higher doses, taking the drug earlier in the evening, daytime preoccupation with the next dose — is the first step.
Tapering should be medically supervised, especially at doses above 20 mg/day, where abrupt discontinuation risks withdrawal seizures.[6] A gradual dose reduction over weeks to months, sometimes with temporary benzodiazepine substitution, is standard practice. Sleep disturbance during tapering is expected and temporary — rebound effect insomnia is a withdrawal symptom, not a sign that the drug is still needed.
Support resources include prescriber consultation, cognitive behavioral therapy for insomnia (CBT-I) as a non-pharmacological alternative, and peer support communities for sedative-hypnotic dependence.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing is slow, shallow, or has stopped
- Person is unconscious and cannot be roused
- Blue or grey discoloration of lips or fingertips
- Seizure activity (especially in someone who has abruptly stopped high-dose use)
Immediate steps:
- 1. Call emergency services
- 2. Place the person in the recovery position (on their side) if unconscious but breathing
- 3. Monitor breathing continuously until help arrives
- 4. Do NOT induce vomiting
- 5. Do NOT administer naloxone — it will not reverse zolpidem's effects
What to tell the dispatcher: Name the substance (zolpidem/Ambien), estimated amount taken, time of ingestion, any other substances involved, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agent: Flumazenil is the specific antidote for zolpidem overdose and is administered intravenous by medical professionals.[7][18]
Legal Status[edit]
Zolpidem is internationally controlled under Schedule IV of the United Nations Convention on Psychotropic Substances, following WHO recommendation in 2001. This scheduling reflects recognized medical utility as a hypnotic alongside acknowledged abuse and dependence potential. Domestic scheduling varies but consistently classifies zolpidem as a prescription-only controlled substance with restrictions on supply duration and refill frequency.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International | Schedule IV, UN Convention on Psychotropic Substances (2001) | WHO-recommended; binding on all signatories. Requires import/export authorization and prescription controls. |
| United States | Schedule IV (Controlled Substances Act) | Prescription required; CIV labeling on all formulations. FDA label includes boxed warning for complex sleep behaviors. Generic formulations widely available following patent expiry. |
| United Kingdom | Class C (Misuse of Drugs Act 1971); Schedule 4, Part I | Prescription limited to 28 days' supply. No safe custody requirements. Subject to controlled drug prescription-writing standards. |
| Canada | Benzodiazepines and Other Targeted Substances Regulations | Prescription required. Regulated alongside benzodiazepines despite structural distinction. Provincial formulary coverage varies. |
| Australia | Schedule 4 (Prescription Only Medicine) | Reports of increasing misuse have prompted rescheduling debates. Real-time prescription monitoring implemented in several states. |
| European Union | Prescription-only (varies by member state) | Recommended for short-term use (≤4 weeks) per European Insomnia Guideline.[36] Individual member states impose additional restrictions on supply duration. |
Zolpidem's structural distinction from benzodiazepines does not exempt it from controlled substance regulations in any major jurisdiction. It is explicitly scheduled by name rather than captured by analogy under structural analog act provisions.
references
- [1] ^abcdSoderhielm PC, Balle T, Bak-Nyhus S, Zhang M, Hansen KM, Ahring PK, Jensen AA (2018) Probing the molecular basis for affinity/potency- and efficacy-based subtype-selectivity exhibited by benzodiazepine-site modulators at GABAA receptors — Biochemical Pharmacology doi:10.1016/j.bcp.2018.08.019
- [2] ^abGreenblatt DJ, Roth T (2012) Zolpidem for insomnia — Expert Opinion on Pharmacotherapy doi:10.1517/14656566.2012.667074
- [3]
- [4]
- [5]
- [6]